Scientific communications

Take advantage of new available seats on board or our upcoming shuttle session, scheduled by early May, to cost-effectively run your candidates on our robust M2 macrophage polarization assaythereby saving up to 25% full cost.

Digital pathology for tumor immune infiltrate analysis and patient selection
To assess whether or not the tumor immune contexture was predictive of response to the Avelumab-Regorafenib combination regimen, Explicyte developed and ran, on baseline FFPE samples, a multiplexed immunohistofluorescence panel consisting of CD8, PD1, PDL1, CD163, IDO1, and PanKeratin markers, in addition to Dapi (Discovery XT, Roche Diagnostics).

Explicyte is planning a new cost-effective in vivo shuttle session by end of February and thus provides an opportunity to speed up your new cancer therapy discovery process.

It therefore becomes primordial to benefit from a technological platform that allows to deal with the tumor biology complexity/heterogeneity and get specific investigations in compartments of interest (e.g. tumor vs stroma). Thanks to the GeoMx platform (Nanostring Inc.), which combines the spatial resolution of immunohistofluorescence with the high-plex gene/protein expression analysis, the Digital Spatial Profiling (DSP) revolution has started.

We have fully set up and characterized a syngeneic Renca renal mouse model recapitulating most of the human RCC condition features. Indeed, our model displays an enriched tumor microvascular environment and relatively low immune infiltration - nevertheless constituted of a strong Myeloid-Derived Suppressor Cells (MDSCs) proportion.

To deal with the current challenge of a qualitative and quantitative tumor immune landscape characterization, we have set up a fully integrated platform spanning from FFPE slide preparation and staining, to image digitization and analysis.

Explicyte is indeed planning a new in vivo shuttle session by mid-October, to be held on a series of syngeneic tumor-bearing mouse models such as MCA025 sarcoma, 4T1 & EMT6 breast cancer, MC38 & CT26 colon cancer or Renca renal cancer, among others.

Macrophages - one of the most abundant antigen-presenting cells - represent by themselves a wide group of functionally-different subpopulations involved in several immunological functions, including inflammatory responses and tissue homeostasis maintain & repair.

Because of metastatic development of the disease, among other characteristics, and regardless of survival data, breast cancer was shown to be particularly difficult to treat. However, metastases as well as resistance to therapies continue to be a great challenge and the development of new therapeutic strategies is increasingly necessary.

Take advantage of our upcoming in vitro shuttle session scheduled in early July on our validated M2 macrophage suppression assay, to assess novel immunotherapeutics in time and cost-effective manner.